An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown that the commonly used high-cholesterol drug simvastatin cannot slow ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

[T]he epidemiology of multiple sclerosis is quite unique because there is a very striking geographical distribution. “It ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

OSU scientists created nanoparticles that deliver anti-inflammatory drugs across the blood-brain barrier, offering hope for ...